Review of Anti-inflammatory and Anti-viral therapeutics for hospitalized patients infected with SARS-CoV-2

ABSTRACT

Synopsis SARS-CoV-2 infection leads to dysregulation of immune pathways. Therapies focusing on suppressing cytokine activity have some success. Current evidence supports the use of dexamethasone in hospitalized patients requiring oxygen to decrease mortality. IL-6 inhibitors like tocilizumab and sarilumab are also beneficial in hypoxemic patients, if used early. JAK inhibition in combination with glucocorticoids is emerging as a potential therapeutic option for patients with moderate to severe symptoms. Data on the role of anakinra, hyperimmune immunoglobulin/convalescent plasma, or plasma purification is limited.